Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Realizing the full potential of genome editing requires the development of efficient and broadly applicable methods for delivering programmable nucleases and donor templates for homology-directed repair (HDR). The RNA-guided Cas9 endonuclease can be introduced into cells as a purified protein in complex with a single guide RNA (sgRNA). Such ribonucleoproteins (RNPs) can facilitate the high-fidelity introduction of single-base substitutions via HDR following co-delivery with a single-stranded DNA oligonucleotide. However, combining RNPs with transgene-containing donor templates for targeted gene addition has proven challenging, which in turn has limited the capabilities of the RNP-mediated genome editing toolbox. Here, we demonstrate that combining RNP delivery with naturally recombinogenic adeno-associated virus (AAV) donor vectors enables site-specific gene insertion by homology-directed genome editing. Compared to conventional plasmid-based expression vectors and donor templates, we show that combining RNP and AAV donor delivery increases the efficiency of gene addition by up to 12-fold, enabling the creation of lineage reporters that can be used to track the conversion of striatal neurons from human fibroblasts in real time. These results thus illustrate the potential for unifying nuclease protein delivery with AAV donor vectors for homology-directed genome editing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Combining Cas9 ribonucleoprotein (RNP) and adeno-associated virus (AAV) donor delivery facilitates gene correction in HEK293T cells. (A) Schematic representation of the GFP reporter system. Lightning bolt indicates approximate position of the RNP cleavage site. The sgRNA target site in GFPΔ35 is shown. Abbreviations are as follows: ITR, inverted terminal repeat; IRES, internal ribosome entry site; LTR, long terminal repeat; UbC, ubiquitin C promoter; PAM, protospacer adjacent motif. (B) Cartoon illustrating RNP and AAV delivery to cells synchronized at G2/M phase. (C) Percentage of GFP positive HEK293T reporter cells following delivery of different combinations of plasmid donor (800 ng), Cas9–sgRNA expression vector (800 ng), AAV donor (multiplicity of infection [MOI] = 100 000) and RNP (300 pmol). (D) Percentage of GFP positive reporter cells following treatment with RNP (300 pmol) and AAV donor (MOI = 100 000) in the presence or absence of 200 ng/ml nocodazole. (E and F) Percentage of GFP positive reporter cells following treatment with (E) increasing amounts of RNP and AAV donor or (F) RNP (300 pmol) and AAV donor (MOI = 100 000) in the presence or absence of 1 μM Scr7. In all cases, AAV donor was added to cells 16 h before RNP delivery. All cells were treated with 200 ng/ml of nocodazole unless otherwise indicated. Values are means (n = 3) and error bars indicate S.D. ***P < 0.0005; unpaired t-tests.](https://figures.cochat.ai/paper-figures/a7c6a5a9c7dc492e97f6e3c56bfae816/targeted-gene-knock-in-by-homology-directed-genome-editing-using-cas9-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This delivery mode can reduce possible off-target mutations relative to delivering Cas9-encoding DNA or mRNA due to the short half-life of RNPs 76,85-87 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 2×
“The Cas9 protein from Streptococcus pyogenes (SpCas9) was expressed from pMJ915 (Addgene #69090) in Escherichia coli Rosetta 2 cells (EMD Millipore) and purified as previously described (1).”
BackgroundMethodSelf-citationMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Self-citationKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 2×
“In fact, due to their rapid action and fast turnover, RNPs yield fewer off-target effects than methods that rely on transient expression from nucleic acids (18,19,21).”
Background
Cited by
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Self-citationFunctional Genetic Variants Revealed by Massively Parallel Precise Genome Editing
Sharon, E., Chen, S.-A. A., Khosla, N. M., Smith, J. D., Pritchard, J. K., & Fraser, H. B. (2018) · Cell · doi:10.1016/j.cell.2018.08.057 · Cited by 225
“We expect that transient expression of the retronmsDNA using lowMOI vectorsmay circumvent this limitation and enable highly parallel precise Fhl1/Rap1 binding sites (Harbison et al., 2004); all five variants affect fitness in ss effects (Figure 2E). by up to 50 bp; the agreement decreases at larger distances, but is s…”
BackgroundIn vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Fu, Y.-W., Dai, X.-Y., Wang, W.-T., Yang, Z.-X., Zhao, J.-J., Zhang, J.-P., Wen, W., Zhang, F., Oberg, K. C., Zhang, L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1251 · Cited by 180
Carlson-Stevermer, J., Abdeen, A. A., Kohlenberg, L., Goedland, M., Molugu, K., Lou, M., & Saha, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01875-9 · Cited by 170
CRISPR-Cas9-mediated homology-directed repair for precise gene editing
Liao, H., Wu, J., VanDusen, N. J., Li, Y., & Zheng, Y. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102344 · Cited by 164
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
Chen, S., Sun, S., Moonen, D. P. I., Lee, C., Lee, A. Y.-F., Schaffer, D. V., & He, L. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.103 · Cited by 139
Self-citationGene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing
Maule, G., Arosio, D., & Cereseto, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113903 · Cited by 110
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics
Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 102
Allen, D. G., Rosenberg, M., & Hendel, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617910 · Cited by 95
Recent Advances in the Application of CRISPR/Cas9 Gene Editing System in Poultry Species
Khwatenge, C. N., & Nahashon, S. N. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.627714 · Cited by 83
Wen, W., Quan, Z.-J., Li, S.-A., Yang, Z.-X., Fu, Y.-W., Zhang, F., Li, G., Zhao, M., Yin, M., Xu, J., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02462-4 · Cited by 81
Suchy, F. P., Karigane, D., Nakauchi, Y., Higuchi, M., Zhang, J., Pekrun, K., Hsu, I., Fan, A. C., Nishimura, T., Charlesworth, C. T., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02171-w · Cited by 69
Efficient Homology-Directed Repair with Circular Single-Stranded DNA Donors
Iyer, S., Mir, A., Vega‐Badillo, J., Roscoe, B. P., Ibraheim, R., Zhu, L. J., Lee, J., Liu, P., Luk, K., Mintzer, E., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0058 · Cited by 69
Bollen, Y., Post, J., Koo, B.-K., & Snippert, H. J. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky571 · Cited by 53
Raikwar, S. P., Kikkeri, N. S., Sakuru, R. C., Saeed, D., Zahoor, H., Premkumar, K., Mentor, S., Thangavel, R., Dubova, I., Ahmed, M. E., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09849-y · Cited by 54
Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs
Stahl, E. C., Sabo, J. K., Kang, M. H., Allen, R., Applegate, E., Kim, S., Kwon, Y., Seth, A., Lemus, N., Salinas-Rios, V., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.019 · Cited by 51
Self-citationFully defined NGN2 neuron protocol reveals diverse signatures of neuronal maturation
Shan, X., Zhang, A., Rezzonico, M. G., Tsai, M., Sánchez-Priego, C., Zhang, Y., Chen, M. B., Choi, M., López, J. M. A., Phu, L., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100858 · Cited by 51
Mencía, Á., Chamorro, C., Bonafont, J., Duarte, B., Holguín, A., Illera, N., Llames, S. G., Escamez, M. J., Haußer, I., Río, M. D., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.01.009 · Cited by 51
Homology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing
Zhang, X., Li, T., Ou, J., Huang, J., & Liang, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00838-7 · Cited by 51
Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment
Zhou, S., Li, Y., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70 · Cited by 45
Bonafont, J., Mencía, Á., Chacón-Solano, E., Srifa, W., Vaidyanathan, S., Romano, R., García, M., Hervás-Salcedo, R., Ugalde, L., Duarte, B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.019 · Cited by 45
CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells
Dever, D. P., Scharenberg, S. G., Camarena, J., Kildebeck, E., Clark, J. T., Martin, R. M., Bak, R. O., Tang, Y., Dohse, M., Birgmeier, J. A., et al. (2019) · iScience · doi:10.1016/j.isci.2019.04.036 · Cited by 43
Wilson, D. R., Rui, Y., Siddiq, K., Routkevitch, D., & Green, J. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00963 · Cited by 42
Lee, J. H., Han, J. P., Song, D. W., Lee, G. S., Choi, B. S., Kim, M., Lee, Y., Kim, S., Lee, H., & Yeom, S. C. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.008 · Cited by 41
Szydlowski, L. M., Lan, T. C. T., Shibata, N., & Goryanin, I. (2020) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2020.109564 · Cited by 36
In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
Nyberg, W. A., Wang, C. H., Ark, J., Liu, C., Clouden, S., Qualls, A., Caryotakis, S. E., Wells, E., Simon, K. E., Garza, C., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.009 · Cited by 34
Disruptive Technology: CRISPR/Cas-Based Tools and Approaches
Patsali, P., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00391-4 · Cited by 34
Pesch, T., Bonati, L., Kelton, W., Parola, C., Ehling, R. A., Csepregi, L., Kitamura, D., & Reddy, S. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02630 · Cited by 34
Shakirova, A. I., Karpov, T. E., Komarova, Y., & Lepik, K. V. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1068637 · Cited by 34
Lee, B., Gin, A. L., Wu, C., Singh, K., Grice, M. Z., Mortlock, R. D., Abraham, D. M., Fan, X., Zhou, Y., Aljanahi, A. A., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.02.010 · Cited by 33
Ways of improving precise knock-in by genome-editing technologies
Smirnikhina, S., Anuchina, A. A., & Лавров, А. В. (2018) · Human Genetics · doi:10.1007/s00439-018-1953-5 · Cited by 32
Mutations in NlInR1 affect normal growth and lifespan in the brown planthopper Nilaparvata lugens
Zhao, Y. J., Huang, G., & Zhang, W. (2019) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2019.103246 · Cited by 32
CRISPR/Cas9 ribonucleoprotein-mediated knockin generation in hTERT-RPE1 cells
Ghetti, S., Burigotto, M., Mattivi, A., Magnani, G., Casini, A., Bianchi, A., Cereseto, A., & Fava, L. L. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100407 · Cited by 32
Improvement of baculovirus as protein expression vector and as biopesticide by CRISPR/Cas9 editing
Pazmiño‐Ibarra, V., Mengual‐Martí, A., Targovnik, A. M., & Herrero, S. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27139 · Cited by 30
Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
Engineering guide RNA to reduce the off-target effects of CRISPR
Wu, J., & Yin, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.003 · Cited by 29
Fuentes, C., & Schaffer, D. V. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.003 · Cited by 28
Self-citationTransplacental Gene Delivery (TPGD) as a Noninvasive Tool for Fetal Gene Manipulation in Mice
Nakamura, S., Watanabe, S., Ando, N., Ishihara, M., & Sato, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235926 · Cited by 27
Viney, L., Bürckstümmer, T., Eddington, C., Mietzsch, M., Choudhry, M. S., Henley, T., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.02023-20 · Cited by 27
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity
Kararoudi, M. N., Tullius, B. P., Chakravarti, N., Pomeroy, E. J., Moriarity, B. S., Béland, K., Colamartino, A., Haddad, É., Chu, Y., Cairo, M. S., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.11.006 · Cited by 26
Zhang, Y., Arango, G., Li, F., Xiao, X., Putatunda, R., Yu, J., Yang, X. F., Wang, H., Watson, L. T., Zhang, L., et al. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0394-2 · Cited by 26
Anderson, W., Thorpe, J., Long, S. A., & Rawlings, D. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900848 · Cited by 25
Xiao, Q., Min, T., Ma, S., Hu, L., Chen, H., & Lu, D. (2018) · Molecular Genetics and Genomics · doi:10.1007/s00438-018-1437-2 · Cited by 24
Editing out HIV: application of gene editing technology to achieve functional cure
Xun, J., Zhang, X., Guo, S., Lu, H., & Chen, J. (2021) · Retrovirology · doi:10.1186/s12977-021-00581-1 · Cited by 24
Designing A Transgenic Chicken: Applying New Approaches toward A Promising Bioreactor.
Bahrami, S., Amiri‐Yekta, A., Daneshipour, A., Jazayeri, S. H., Mozdziak, P. E., Sanati, M. H., & Gourabi, H. (2020) · PubMed Central · doi:10.22074/cellj.2020.6738 · Cited by 23
Systems of Delivery of CRISPR/Cas9 Ribonucleoprotein Complexes for Genome Editing
Амирханов, Р. Н., & Stepanov, G. A. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019060025 · Cited by 23
Lindel, F., Dodt, C., Weidner, N., Noll, M., Bergemann, F., Behrendt, R., Fischer, S., Dietrich, J., Cartellieri, M., Hamann, M. V., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.006 · Cited by 22
A novel technique for large-fragment knock-in animal production without ex vivo handling of zygotes
Abe, M., Nakatsukasa, E., Natsume, R., Hamada, S., Sakimura, K., Watabe, A. M., & Ohtsuka, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-29468-1 · Cited by 20
Han, J. P., Lee, Y., Lee, J. H., Chung, H. Y., Lee, G. S., Nam, Y. R., Choi, M., Moon, K., Lee, H., Lee, H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102050 · Cited by 19
Kissling, L., Monfort, A., Swarts, D. C., Wutz, A., & Jínek, M. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.10.028 · Cited by 18
A Practical Guide to Genome Editing Using Targeted Nuclease Technologies
Porter, S. N., Levine, R. M., & Pruett‐Miller, S. M. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180022 · Cited by 18
Intracellularly synthesized ssDNA for continuous genome engineering
Liu, W., Pan, Y., Zhang, Y., Dong, C., Huang, L., & Lian, J. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.10.011 · Cited by 15
Li, Z., Wang, X., Janssen, J. M., Liu, J., Tasca, F., Hoeben, R. C., & Gonçalves, M. A. F. V. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1213 · Cited by 15
Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1
Désaulniers, K., Ortiz, L., Dufour, C., Claudel, A., Plourde, M. B., Mérindol, N., & Berthoux, L. (2020) · Viruses · doi:10.3390/v13010024 · Cited by 14
Mishra, T. K., Bhardwaj, V., Ahuja, N., Gadgil, P., Ramdas, P., Shukla, S., & Chande, A. G. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.003 · Cited by 13
Guarding the genome: strategies for off-target detection and minimization in CRISPR/Cas9 system
Lotfi, M., Yazdi, Z. F., Hashemi, M. R., Abbaszadegan, M. R., & Sharif, S. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2581677 · Cited by 8
Boddu, P. C., Gupta, A. K., Kim, J.-S., Neugebauer, K. M., Waldman, T. A., & Pillai, M. M. (2021) · Communications Biology · doi:10.1038/s42003-021-02690-1 · Cited by 8
Bachtarzi, H. (2017) · Regenerative Medicine · doi:10.2217/rme-2017-0095 · Cited by 7
Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System
Devaraju, N., Rajendiran, V., Ravi, N. S., & Mohankumar, K. M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1979-7_20 · Cited by 7
Genome editing technologies and their potential to treat neurologic disease
Madigan, N. N., Staff, N. P., Windebank, A. J., & Benarroch, E. E. (2017) · Neurology · doi:10.1212/wnl.0000000000004558 · Cited by 7
Protein Carrier Adeno-Associated Virus
Hoffmann, M. D., Sorensen, R. J., Extross, A., He, Y., & Schmidt, D. (2025) · ACS Nano · doi:10.1021/acsnano.5c01498 · Cited by 6
Guo, P., Yu, C., Wang, Q., Zhang, R., Meng, X., & Feng, Y. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.004 · Cited by 6
A synthetic mitochondrial-based vector for therapeutic purposes
Renteln, M. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.05.014 · Cited by 6
Xie, K., Starzyk, J., Majumdar, I., Rincones, K., Tran, T. T. D., Lee, D., Niemi, S., Famiglietti, J., Suter, B., Shan, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.01.518578 · Cited by 6
Tennant, P. A., Foster, R. G., Dodd, D. O., Sou, I. F., McPhie, F., Younger, N. T., Murphy, L. C., Pearson, M. W., Vernay, B., Keighren, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.14.200170 · Cited by 5
Haideri, T., Lin, J., Bao, X., & Lian, X. L. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2024.03.005 · Cited by 4
Hamada, T., Yokoyama, S., Akahane, T., Matsuo, K., & Tanimoto, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010500 · Cited by 4
Impact assessment of exploratory wells offshore south Florida
Shinn, E. A., Lidz, B. H., & Dustan, P. (1989) · doi:10.67297/000bae · Cited by 4
Chen, J., Zhang, C.-C., Sun, J., Zhang, Y., Luo, M.-S., & Zhang, W.-Q. (2024) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2024.104244 · Cited by 3
Qiu, L., Kumpf, S. W., Oziolor, E. M., Sheehan, M. J., Finley, J. E., Rubitski, D. M., Qian, J., Gosink, M. M., Kopec, A. K., Lanz, T. A., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117229 · Cited by 3
Sentmanat, M. F., Wang, Z. T., Kouranova, E. V., Peters, S., Chan, W. C., Lin, J., Miao, Y., White, J. M., Wallace, M., & Cui, X. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag237 · Cited by 3
Widjaya, M. A., Ju, J.-C., & Lee, S. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10345-9 · Cited by 3
Key to Delivery: The (Epi-)genome Editing Vector Toolbox
Just, S., & Büning, H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_7 · Cited by 3
Manufacturing and Delivering Genome-Editing Proteins
Liu, J., Liang, Y.-J., Ren, P.-L., & Gaj, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8799-3_19 · Cited by 3
Self-citationCRISPR: Genome Editing and Beyond
Aiana, & Singh, K. (2022) · Springer eBooks · doi:10.1007/978-981-16-4345-3_12 · Cited by 2
Molecular and Cellular Engineering of B Cells for Immunotherapy Applications
Pesch, T. (2019) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000331802 · Cited by 2
Bandyopadhyay, S., Douglass, J., Kapell, S., Khan, N., Feitosa-Suntheimer, F., Klein, J. A., Temple, J., Brown-Culbertson, J., Tavares, A. H., Saeed, M., et al. (2021) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkab169 · Cited by 1
Genome Editing in Gene and Cell-Based Therapies
Ganapathy, S., & Gupta, S. K. (2020) · ACTA SCIENTIFIC MICROBIOLOGY · doi:10.31080/asmi.2020.03.0580
Production of induced regulatory T-cells through CRISPR/Cas9-based gene editing
Tschann, M. M. (2018) · University of Minnesota Digital Conservancy (University of Minnesota)
Reprogramming T Cells to Interrogate Intracellular Disease Signatures
Ho, P. (2019) · eScholarship (California Digital Library)
Karyotype diversification in colorectal cancer
Bollen, Y. (2022) · doi:10.3990/1.9789036553506
Aplicación de tecnología de edición de genes como alternativa de tratamiento en pacientes con VIH
Cabrera-Ávila, P., Solano, F. D. C., & Flores-Montesinos, C. (2023) · 593 Digital Publisher CEIT · doi:10.33386/593dp.2023.5.2001
Recent Development in in vivo Clinical Gene Therapy Platforms
Murphy, J. E., & Owens, J. M. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch2
Peddinti, S., Peddinti, S., & James, M. (2024) · Journal of Student Research · doi:10.47611/jsr.v13i2.2512
Wen, W., Quan, Z.-J., Li, S.-A., Yang, Z.-X., Fu, Y.-W., Zhang, F., Li, G.-H., Zhao, M., Yin, M.-D., Xu, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15982471
Wen, W., Quan, Z.-J., Li, S.-A., Yang, Z.-X., Fu, Y.-W., Zhang, F., Li, G.-H., Zhao, M., Yin, M.-D., Xu, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15982474
TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
Peng, X., Huang, J., Lv, S., Zhang, J., Zhang, L., Liu, H., Liu, Y., Qiao, Z., Wei, F., & Su, B. (2026) · Advanced Science · doi:10.1002/advs.202512978
Hara, H., Uosaki, H., Nakahara, F., Inoue, M., & Hanazono, Y. (2026) · Genes to Cells · doi:10.1111/gtc.70129
Scalisi, G., Sakkal, A., Lacombe, L., Sarnari, F., Rouillon, M., Rosiello, M., Tachtsidi, A., Galbiati, P., Corre, G., Oustelandt, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.15.732298
Rezaee, M., Izadi, F., Nobaharian, S., Hassani, L., Rezaei, E., Amini, S. S., Pourfathollah, A. A., Kowsari, A., Naeimi, S., Varnamkhasti, K. K., et al. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00824-0
Metadata
- Authors
- Gaj, T., Staahl, B. T., Rodrigues, G. M. C., Limsirichai, P., Ekman, F. K., Doudna, J. A., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- University of Lisbon (PT)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gaj, Thomas
- Staahl, Brett T.
- Doudna, Jennifer A.
- Schaffer, David V.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-02
- Volume
- 45
- Issue
- 11
- Pages
- e98-e98
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5499784
- OpenAlex
- W2594121715
- Cited by
- 89
- References
- 76
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 12 · 2023: 6 · 2022: 8 · 2021: 13 · 2020: 9 · 2019: 17 · 2018: 10 · 2017: 5
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- F. Hoffmann-La Roche
- Innovative Genomics Institute
- National Institutes of Health
- University of California, San Francisco
- Fundação para a Ciência e a Tecnologia (SFRH/BD/89374/2012)
- National Eye Institute (R01EY022975)
- National Institute of General Medical Sciences (F32GM113446)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- homology-directed repair, CRISPR/Cas9 ribonucleoprotein, adeno-associated virus vectors, gene knock-in, striatal neurons, fibroblast-to-neuron conversion, single guide RNA
- MeSH terms
- CRISPR-Associated Protein 9, Dependovirus, Bacterial Proteins, Base Sequence, Cell Differentiation, Endonucleases, Fibroblasts, Genetic Engineering, Genetic Vectors, Humans, Neurons, Sequence Homology, Nucleic Acid, Genome, Human, Gene Knock-In Techniques, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.